Clinical Trials for Multiple Myeloma in Relapse

Find clinical trials for multiple myeloma in relapse. Discover research opportunities and treatment options in your area.

30 Active Trials Found

Showing 30 trials on this page

Page 1 of 2

Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma

NCT ID: NCT07032129

This clinical trial is testing a new treatment for people with a type of blood cancer called multiple myeloma, specifically for patients whose cancer has come back or has not responded to standard ...

Recruiting

Phase: PHASE1 Type: interventional Locations: Beijing, Beijing, China

UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma

NCT ID: NCT06698744

This clinical trial is studying a new treatment called UF-KURE-BCMA CAR-T cells for patients with relapsed or refractory multiple myeloma, which is a type of blood cancer. The aim is to see if thes...

Not yet recruiting

Phase: PHASE1 Type: interventional Locations: Cleveland, Ohio, United States

TriPRIL CAR T Cells in Multiple Myeloma

NCT ID: NCT05020444

This clinical trial is studying a new treatment called TriPRIL CAR T Cells for patients with multiple myeloma, which is a type of blood cancer that can return after treatment or become resistant to...

Recruiting

Phase: PHASE1 Type: interventional Locations: Boston, Massachusetts, United States

Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse

NCT ID: NCT06827860

This clinical trial is studying a new treatment called talquetamab for elderly patients with multiple myeloma who are experiencing an early relapse after previous therapies. Multiple myeloma is a t...

Recruiting

Phase: PHASE2 Type: interventional Locations: New York, New York, United States

Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma

NCT ID: NCT06880601

This clinical trial is studying a combination treatment for adults with multiple myeloma, a type of blood cancer that has come back after treatment or hasn't responded to previous therapies. The tr...

Not yet recruiting

Phase: PHASE2 Type: interventional

Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory T(11;14) Multiple Myeloma

NCT ID: NCT05853965

This clinical trial is testing a combination of two drugs, belantamab mafodotin and venetoclax, to see how safe and effective they are in treating patients with a specific type of multiple myeloma ...

Recruiting

Phase: PHASE1 Type: interventional Locations: Heidelberg, , Germany, Chemnitz, , Germany +3 more

a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

NCT ID: NCT04776330

This clinical trial is studying a new treatment called BCMA-targeted prime CAR-T cell therapy for patients with relapsed or refractory multiple myeloma. Multiple myeloma is a type of blood cancer t...

Recruiting

Phase: PHASE1 Type: interventional Locations: Kunming, Yunnan, China

BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

NCT ID: NCT04271644

**Summary of the Clinical Trial: BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma** This clinical trial is testing a new treatment called BCMA-targeted CAR-T cell therapy ...

Recruiting

Phase: PHASE1 Type: interventional Locations: Kunming, Yunnan, China

Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.

NCT ID: NCT06846905

This clinical trial is studying a new way to treat multiple myeloma, a type of blood cancer that can come back after treatment. The focus is on a special type of medicine called bispecific antibodi...

Recruiting

Type: observational Locations: Toulouse, , France

All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma

NCT ID: NCT06158412

This clinical trial is studying a new treatment approach for patients with a type of blood cancer called multiple myeloma, particularly those whose disease has come back or hasn’t responded well to...

Recruiting

Phase: PHASE2 Type: interventional Locations: Xiamen, Fujian, China

HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM

NCT ID: NCT06822972

This clinical trial, called HCMT/MM2401, is investigating a new treatment approach for patients with relapsed or refractory multiple myeloma (RRMM), a type of blood cancer. The trial is studying th...

Not yet recruiting

Phase: PHASE2 Type: interventional

A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

NCT ID: NCT06115135

This clinical trial is studying the combination of three medications—venetoclax, isatuximab, and dexamethasone—to treat patients with relapsed or refractory multiple myeloma who have a specific gen...

Recruiting

Phase: PHASE2 Type: interventional Locations: Omaha, Nebraska, United States, West Hollywood, California, United States

A Trial of Selinexor, Ruxolitinib and Methylprednisolone

NCT ID: NCT06225310

This clinical trial is studying a combination of three medications—Selinexor, Ruxolitinib, and Methylprednisolone—to see how effective they are in treating patients with Multiple Myeloma, a type of...

Recruiting

Phase: PHASE1 Type: interventional Locations: West Hollywood, California, United States

Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma

NCT ID: NCT05673083

This clinical trial, called "Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma," is exploring how a program called All4Cure affects patients with multiple myeloma...

Recruiting

Type: observational Locations: Tacoma, Washington, United States, Fayetteville, Arkansas, United States +5 more

LMY-920 for Treatment of Relapsed or Refractory Myeloma

NCT ID: NCT05546723

This clinical trial is studying a new treatment called LMY-920 for patients with relapsed or refractory multiple myeloma, a type of blood cancer. The goal is to see if a special kind of immune cell...

Recruiting

Phase: PHASE1 Type: interventional Locations: Cleveland, Ohio, United States

BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma

NCT ID: NCT06644443

This clinical trial is studying a new treatment called BCMA-GPRC5D CAR-T therapy for patients with relapsed or refractory multiple myeloma, which is a type of blood cancer that often comes back aft...

Recruiting

Phase: PHASE1 Type: interventional Locations: Shenzhen, Guangdong, China

Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma

NCT ID: NCT06485076

This clinical trial is looking at the benefits of early palliative care for patients with multiple myeloma and aggressive B cell lymphoma, which are types of blood cancers. Palliative care focuses ...

Recruiting

Phase: NA Type: interventional Locations: Toronto, , Canada

Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells

NCT ID: NCT04813653

This clinical trial is studying a new treatment approach for patients with relapsed multiple myeloma, a type of blood cancer that has returned after previous treatments and is resistant to them. Th...

Recruiting

Phase: PHASE1 Type: interventional Locations: Tel Aviv, , Israel

A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies

NCT ID: NCT05836896

This clinical trial is designed to test a new treatment called MDC-CAR-BCMA001, which uses specially modified immune cells known as CAR T-cells to target certain types of blood cancers, specificall...

Recruiting

Phase: PHASE1 Type: interventional Locations: Dresden, , Germany

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

NCT ID: NCT04176718

This clinical trial is investigating a new treatment for patients with multiple myeloma, a type of blood cancer that can return after treatment or resist previous therapies. The study is looking at...

Recruiting

Phase: PHASE2 Type: interventional Locations: Boston, Massachusetts, United States, Boston, Massachusetts, United States +2 more

Related Conditions

Breast Cancer View clinical trials → Stroke View clinical trials → Obesity View clinical trials → Cancer View clinical trials → Healthy View clinical trials → Prostate Cancer View clinical trials →

Search All Trials Browse All Conditions